Prediction of short- and medium-term efficacy of biosimilar infliximab therapy. Do trough levels and antidrug antibody levels or clinical and biochemical markers play a more important role?

Hasonló tételek

• Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease
  Szerző: Pallagi-Kunstár Éva, et al.
  Megjelent: (2014)
• Switching from infliximab to biosimilar in inflammatory bowel disease
  Szerző: Milassin Ágnes, et al.
  Megjelent: (2019)
• Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease
  Szerző: Bor Renáta, et al.
  Megjelent: (2017)
• Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-alpha level and the efficacy of TNF-inhibitor therapy in psoriasis
  Szerző: Kui Róbert, et al.
  Megjelent: (2016)
• Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort
  Szerző: Gönczi Lóránt, et al.
  Megjelent: (2017)